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Abstract: The objective of this exploratory, multicenter, randomized, double-blind study, was 
to evaluate the efficacy and safety/tolerability of milnacipran and venlafaxine administered at 
flexible doses (100, 150 or 200 mg/day, bid administration) for 24 weeks (including 4 weeks 
up titration period) in the outpatient treatment of adults presenting with a moderate or severe 
episode of major depressive disorder (MDD) without high suicidal risk (MINI-DSM IV-TR). 
Of the 195 patients included, 134 (68.7%) completed the study. At baseline the two groups were 
similar, except there was a higher proportion of patients whose episode was severe-DSM IV in 
the milnacipran group (63.3% versus 54.0% in the venlafaxine group). The initial MADRS score 
(mean 31.0) decreased progressively during the study, and this decrease was in the two treatment 
groups (n = 177: 90 milnacipran; 87 venlafaxine) at week 24 (observed case/OC, mean change 
–23.1 milnacipran; –22.4 venlafaxine). The rate of MADRS response (reduction  50%) at week 
8 and week 24-last observation carried forward/LOCF was similar in the two groups (week 8: 
64.4% milnacipran; 65.5% venlafaxine; week 24: 70% milnacipran; 77% venlafaxine), as was 
the rate of MADRS remission (score  10) (week 8: 42.2% milnacipran; 42.5% venlafaxine; 
week 24: 52.2% milnacipran; 62.1% venlafaxine). In both groups, the most common adverse 
events were: nausea, dizziness, headache, hyperhidrosis and, in males, genito-urinary problems. 
The overall safety/tolerability and efficacy profiles of milnacipran and venlafaxine administered 
at flexible dosages (up to 200 mg/day) were similar in the long term treatment of adults during 
episodes of MDD in an outpatient setting.
Keywords: major depressive episode, adult, serotonin and norepinephrine reuptake inhibitors, 
milnacipran, venlafaxine
Introduction
With a prevalence of around 10% in the general population, major depressive disorder 
(MDD) is the most common psychiatric problem.1 Strongly associated with general and 
psychiatric co-morbidity (anxiety problems and addictions),2 it is the primary cause 
of physical and mental incapacity.3 Suicide risk is a characteristic of this disorder, 
and 5% of cases of severe depression result in suicide.4 Despite its prevalence and 
detrimental consequences for both individuals and society in general, depression is 
only diagnosed in one in two cases, and it is particularly poorly managed, with less 
than 10% of patients with depression benefiting from antidepressant treatment which Neuropsychiatric Disease and Treatment 2010:6 72
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is appropriate in terms of dose and duration.5 Although it 
is now recognized that the minimum duration of treatment 
with antidepressants necessary in order to prevent relapse 
of a current depressive episode is 6 months, only a few 
randomized, double-blind clinical studies investigating the 
treatment of major depression over this period have been 
carried out.
The antidepressant activity of a molecule is linked to its 
capacity to increase the synaptic concentration of serotonin 
(5-HT) and/or norepinephrine (NE), generally by inhibit-
ing the reuptake of one or both of these neurotransmitters. 
The tricyclic antidepressants (TCAs) have, for a long time, 
been the cornerstone of treatment for major depression, but 
their safety/tolerability profile is poor due to the fact that 
their pharmacological action is not limited to those two 
neurotransmitters. They have been succeeded first by the 
selective serotonin reuptake inhibitors (SSRIs), which are 
slightly less effective, but much better tolerated, and then 
by the serotonin noradrenalin reuptake inhibitors (SNRIs), 
which combine the efficacy of the TCAs with the tolerability 
of the SSRIs.6 Milnacipran (Ixel®) and venlafaxine (Effexor®) 
are both SNRIs, which differ in the ratio of potential reup-
take inhibition of NE:5-HT (estimated to be 1:1 and 1:30 
respectively).7
The recommended dose of milnacipran in major depres-
sion is 100 mg/day. Different studies carried out in this 
indication with doses from 150 to 300 mg/day have sug-
gested that some patients may benefit from higher doses.8–10 
These studies and others carried out in fibromyalgia with 
a dose of 200 mg/day,11,12 have shown that milnacipran 
administered at these higher dosages both as loading 
dose and over the long term has a good safety/tolerability 
profile. Venlafaxine is prescribed in this indication at 
recommended doses in outpatients from 75 to 225 mg/day 
with uptitration at the start of treatment and down titration 
at the end.
The objective of this study was to explore the efficacy and 
long-term safety/tolerability of milnacipran and venlafaxine 
administered in an outpatient setting at doses of 100, 150 and 
200 mg/day for episodes of MDD in adults.
Methods
study design
This was a multi-center, randomized (1:1), double-blind 
study with two parallel treatment arms (milnacipran and 
venlafaxine), conducted over a treatment period of 24 weeks 
in 195 adult outpatients presenting with an episode of recur-
rent, unipolar, moderate-to-severe MDD.
Pre-inclusion procedures
The study protocol was approved by the Comité de Protection 
des Personnes Ile de France III and authorized by the Agence 
Française de Sécurité Sanitaire des Produits de Santé. All 
patients gave written informed consent before participating 
in the study, having first been informed of the methods and 
constraints of the study and their rights about access and 
corrections to the data concerning them.
The patients were selected and followed as outpatients 
through the duration of the study by 50 psychiatrists (hos-
pital, private or a combination) in 21 centers in France. 
To ensure the data collected were homogeneous, all inves-
tigators were trained at study set-up in the standardized use 
of evaluation scales in the study. After a washout period of 
4 to 21 days (depending on ongoing treatments), eligible 
patients were randomized to either milnacipran or venla-
faxine according to a pre-established randomization list. 
Baseline evaluations were carried out prior to any study 
treatment being taken.
study population
Included patients were male or female outpatients aged 
from 18 to 70 years who met the Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition, Text 
Revision (DSM-IV-TR) and using Mini International 
Neuropsychiatric Interview (MINI) French version 
5.0.013 criteria for recurrent, unipolar, moderate-to-severe 
MDD, with neither psychotic features nor high suicidal 
risk. A Montgomery-Åsberg Depression Rating Scale 
(MADRS)14 score  23 was required at inclusion to confirm 
that the intensity of the episode was moderate or severe. 
Patients with anxiety linked to the depression could partici-
pate in the study.
Treatment
The maximum duration of exposure for each patient was 
26 weeks (Figure 1). During the first 4 weeks, the dose was 
administered according to an up titration schedule: 25 mg/day 
(D1–D3), 50 mg/day (D4–D6), 100 mg/day (D7–D13) and 
150 mg/day (D14–D28). At D28, the investigators could 
decide to maintain the dose at 150 mg/day, reduce the dose 
to 100 mg/day or increase the dose to 200 mg/day. At any 
time during the following 20 weeks, the doses of 150 or 
200 mg/day could be reduced for reasons relating to safety 
down to a minimal dose of 100 mg/day. After 24 weeks of 
treatment, the dose was reduced by in stages, by 50 mg/day 
every 5 days. The daily doses were administered in two 
identical doses morning and evening, except the initial dose Neuropsychiatric Disease and Treatment 2010:6 73
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Figure 1 Treatment administration scheme.
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of 25 mg/day (1 dose AM only) and the dose of 150 mg/day 
(50 mg AM and 100 mg PM).
Data collected: methods and timing
Data were collected by the investigators during the following 
study visits:
•  Pre-treatment: selection visit and randomization visit (D1),
•  During treatment: at weeks 2, 4, 6, 8, 12, 18 and 24,
•  Post treatment: end-of-study visit after 5 to 15 days of 
down titration and 10 days without treatment.
The evaluation scales used included the MADRS and the 
Clinical Global Impression of Severity (CGI-S) scales.15
All the scales were assessed at the pre-treatment and 
end-of-study visits. During the study, the MADRS was 
assessed at all the visits, and the CGI-S was assessed at 
weeks 8 and 24.
The rate of MADRS response (reduction in initial score 
of 50%) and remission (score  10) were calculated at 
weeks 8 and 24. The rate of MADRS response and remission 
was also calculated at these time points in the subgroups of 
patients whose episode of depression was severe in intensity 
(DSM-IV-TR) at inclusion and in those patients who had 
a suicidal risk (low or moderate according to the MINI as 
required for inclusion).
Safety/tolerability was evaluated at each visit by the 
collection of adverse events and a complete physical exami-
nation including measurement of cardiovascular parameters 
(arterial blood pressure and heart rate). In addition, ECGs 
were carried out at weeks 4, 6, 8 and 24 and blood tests 
for standard hematology and biochemistry parameters at 
weeks 8 and 24. The procedure for collecting and following 
up adverse events was strictly in compliance with the cur-
rent regulations.
statistical analysis
The statistical analysis was carried out using the program 
SAS (version 9.1.3).
Standard distribution statistics: mean, standard deviation 
(SD), minimum (min) and maximum (max) scores and their 
changes from baseline, were calculated using the observed-
case (OC) approach at all assessment times for the MADRS 
score and the last-observation-carried-forward (LOCF) at 
8 and 24 weeks for both MADRS and CGI-S scores.
The rate of MADRS response and remission at weeks 8 
and 24 (LOCF) was calculated by normal approximation of 
the binomial distribution.
Bilateral exploratory statistical tests at the 5% significance 
level were performed on results at 8 and 24 weeks of:
•  changes from baseline in MADRS score (OC) at each 
visit: mixed model for repeated measures (MMRM),
•  global MADRS response and remission rates (LOCF): 
chi squared.
Results
study population
Of 195 patients randomized (97 milnacipran; 98 venlafaxine), 
134 (68.7%) completed 24 weeks of treatment (60 milnacip-
ran; 74 venlafaxine). In the two groups the main reason for 
premature withdrawal from the study was adverse events 
(19/37 on milnacipran, 10/24 on venlafaxine). No patients 
were lost to follow-up.
The analysis of safety/tolerability was carried out on 
the data for 181 patients (90 milnacipran; 91 venlafax-
ine); 14 patients from a center which did not respect good 
clinical practice were excluded. The efficacy analysis was 
carried out on data from 177 patients (90 milnacipran; 
87 venlafaxine); 4 patients from the venlafaxine group 
did not complete the MADRS evaluation during the first 
8 weeks of treatment.
The demographic characteristics of the patients at inclu-
sion (Table 1) were similar, except that the proportion of 
patients whose episode of depression was severe (DSM-IV) 
was greater in the milnacipran group (63.3% versus 54% in 
the venlafaxine group). The majority of the study population 
was female (60.8%); patient ages ranged from 18 to 69 years, 
with a mean age of 43.7 years. The mean duration of the 
disease was 12.6 years, and the mean duration of the current 
episode was 3.4 months. A previous episode had been treated 
with antidepressants in 87% of patients.
The initial mean MADRS and CGI-S scores in the 
overall population were 31.0 (SD: 4.5), and 5.2 (SD: 0.7) 
respectively, and were not significantly different between the 
treatment groups. This demonstrates the moderate to severe 
intensity of the disease and its symptoms.Neuropsychiatric Disease and Treatment 2010:6 74
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For the majority of patients, the dose achieved at the end 
of the up titration period was either 150 mg/day (30.4% with 
milnacipran and 43.8% with venlafaxine) or 200 mg/day 
(58.2% and 46.3% respectively). At the end of treatment, 
the distribution of doses had not significantly differed from 
D28 in the two groups. Treatment compliance in the two 
groups was good (80% of the planned treatment) in 99% 
of patients at the 8-week visit and 93% of patients at the end 
of treatment visit.
Efficacy
The MADRS score decreased progressively throughout 
the study and was comparable in the two treatment groups 
(Figure 2). The mean [SD] decrease (OC) in the milnacip-
ran and venlafaxine groups respectively was: 6.9 [6.7] and 
7.9 [7.4] after 2 weeks of treatment, 18.8 [7.7] and 18.6 [7.3] 
(pMMRM = 0.95) after 8 weeks of treatment, and 23.1 [7.8] and 
22.4 [7.3] (pMMRM = 0.37) after 24 weeks of treatment.
Table 1 Patient characteristics at inclusion
Milnacipran 
N = 90
Venlafaxine 
N = 91
Total 
N = 181
Males/Females
n (%) 35 (38.9%)/ 
55 (61.1%)
36 (39.6%)/ 
55 (60.4%)
71 (39.2%)/ 
110 (60.8%)
Age (years)
Mean [sD] 44.6 [11.4] 42.7 [12.8] 43.7 [12.1]
Min/Max 19.0/68.0 18.0/69.0 18.0/69.0
BMI (kg/m²)
Mean [sD] 24.2 [4.6] 24.0 [4.3] 24.1 [4.4]
Min/Max 17.4/35.2 16.4/37.3 16.4/37.3
N = 90 N = 87 N = 177
Duration of current episode (months)
Mean [sD] 3.6 [2.8] 3.2 [2.2] 3.4 [2.5]
Min/Max 0.0/17.0 0.0/15.0 0.0/17.0
Severe episode (DSM-IV-TR)
n (%) 57 (63.3%) 47 (54.0%) 104 (58.8%)
Suicide risk (MINI)
n (%) 39 (43.3%) 37 (42.5%) 76 (42.9%)
Low: n (%) 34 (37.8%) 33 (36.3%) 67 (37.0%)
Moderate: n (%) 4 (4.4%) 4 (4.4%) 8 (4.4%)
high: n (%) 1 (1.1%) 0 1 (0.6%)
MADRS
Mean [sD] 31.4 [4.6] 30.7 [4.4] 31.0 [4.5]
Min/Max 23.0/43.0 23.0/43.0 23.0/43.0
CGI-S
Mean [sD] 5.1 [0.7] 5.2 [0.7] 5.2 [0.7]
Min/Max 3.0/6.0 4.0/6.0 3.0/6.0
Abbreviations: cgi-s, clinical global impression of severity; MADRs, Montgomery-
Åsberg Depression Rating scale; sD, standard deviation.
The rate of MADRS response and remission (LOCF) was 
similar, or not clinically different (or statistically different 
where applicable) in the two treatment groups at week 8 and, 
after a further increase, at week 24:
•  In the overall population (n = 177) (Figure 3):
  Response: 64.4% milnacipran; 65.5% venlafaxine 
at week 8 (pchi2 = 0.88), 70.0% milnacipran; 77.0% 
venlafaxine at week 24 (pchi2 = 0.29),
  Remission: 42.2% milnacipran; 42.5% venlafaxine 
at week 8 (pchi2 = 0.97), 52.2% milnacipran; 62.1% 
venlafaxine at week 24 (pchi2 = 0.19);
•  In patients whose episode of depression was severe in 
intensity at inclusion (n = 104) (Figure 4):
  Response: 61.4% milnacipran; 61.7% venlafaxine 
at week 8, 71.9% milnacipran; 74.5% venlafaxine at 
week 24,
  Remission: 29.8% milnacipran; 31.9% venlafaxine at 
week 8, 49.1% milnacipran and 53.2% venlafaxine at 
week 24;
•  Or, in patients with a suicide risk according to the MINI 
(“low” or “moderate” as required for inclusion; n = 75 
patients) (Figure 4):
  Response: 65.8% milnacipran; 59.5% venlafaxine 
at week 8, 71.1% milnacipran; 64.9% venlafaxine at 
week 24,
  Remission (Figure 4): 44.7% milnacipran; 35.1% 
venlafaxine at week 8, 52.6% milnacipran; 54.1% 
venlafaxine at week 24.
In the vast majority of cases, the therapeutic benefit 
achieved at week 8 was maintained over the long term: 
Overall, 93% of the patients who were MADRS responders 
at week 8, were also responders at week 24 (95% 
milnacipran, 87% venlafaxine), while 89.3% of the patients 
who had MADRS remission at week 8 also had remission 
at week 24 (87% milnacipran; 92% venlafaxine). Twelve 
(7%) patients (6 in each group) had response or remission 
at week 8 which was not maintained at week 24. However, 
for 7 of these patients (3 milnacipran; 4 venlafaxine) the 
increase in MADRS score between week 8 and week 24 
was not clinically significant (25% between weeks 8 
and 24).
The global CGI-S score of the severity of the disease 
had significantly decreased at week 8, and this decrease 
was comparable in the two groups: mean [SD] decrease 
of –2.0 [1.4] milnacipran; –2.3 [1.2] venlafaxine: This 
improvement was maintained at week 24, with a mean [SD] 
decrease in CGI-S of –2.3 [1.2] milnacipran and of –2.7 
[1.4] venlafaxine.Neuropsychiatric Disease and Treatment 2010:6 75
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safety/tolerability
During the treatment period, at least one adverse event (AE) 
was reported in 65 patients (72%) in the milnacipran group 
and 67 patients (74%) in the venlafaxine group. The major-
ity of AEs (85% in both groups) were mild or moderate in 
severity.
In the two groups, the most common treatment emer-
gent AEs (occurring in  10% of patients in either group) 
(Figure 5) were gastrointestinal (nausea, constipation and dry 
mouth), neurological (dizziness and headache), cutaneous 
(hyperhidrosis) and cardiac (palpitations). In males, genito-
urinary disorders were also common: testicular pain and 
dysuria were experienced only in the milnacipran group (9% 
and 20% respectively), while orgasmic disorders were only 
reported in the venlafaxine group (17%). In males, there was 
a higher incidence in the venlafaxine group of the following 
Figure 2 changes over time from baseline MADRs total score (Oc).
Note: Values are given as mean ± seM based on Oc analysis.
M
e
a
n
 
c
h
a
n
g
e
 
o
f
 
M
A
D
R
S
 
t
o
t
a
l
 
s
c
o
r
e
Number of days of treatment
Milnacipran Venlafaxine
0
−5
−10
−15
−20
−25
−30
14 28 42 56 70 84 98 112 126 140 154 168
Figure 3 Rate of MADRs response and remission at weeks 8 and 24.
Notes: columns represent the mean values based on LOcF analysis (n = 177). error bars are ± seM.
MADRS response – total study population  MADRS remission – total study population
D56 D168 D56 D168
Milnacipran Venlafaxine Milnacipran Venlafaxine
%
 
o
f
 
r
e
s
p
o
n
d
e
r
s
 
100
90
80
70
60
50
40
30
20
10
0
100
90
80
70
60
50
40
30
20
10
0
%
 
o
f
 
r
e
m
i
t
t
e
d
 
p
a
t
i
e
n
t
sNeuropsychiatric Disease and Treatment 2010:6 76
Olié et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
AEs: dizziness (33% versus 11%), nausea (31% versus 14%), 
hyperhidrosis (25% versus 11%) and tension/agitation and 
bruxism (only in the venlafaxine group, in 14% and 11% of 
patients respectively).
Onset of the majority of the most frequent AEs occurred 
within the first 3 weeks of treatment (except for dizziness 
in the venlafaxine group which occurred over the first 
3 months). Nausea was the event that had the earliest onset 
(within the first 2 days in the majority of cases).
After the end of treatment, the incidence of AEs (particu-
larly dizziness and headache) was greater in the venlafaxine 
group (14% versus 7% in the milnacipran group).
Five patients in the milnacipran group and 7 patients 
in the venlafaxine group experience at least one serious 
AE (SAE) (Table 2). One death occurred during the study 
in a 46-year-old patient who was receiving milnacipran 
150 mg/day, following the rupture of a cerebral arterial 
aneurysm (D88). This event was judged by the investigator 
to be unrelated to the study treatment. Three SAEs (all in 
the venlafaxine group) were judged to be possibly related 
to the study treatment (1 event of worsening depression, 
1 of anxiety related to an overdose of venlafaxine and 1 of 
biliary colic). There were 4 cases of worsening depression 
(3 with venlafaxine and 1 with milnacipran), all of which 
led to hospitalization and had favorable outcome. The three 
treatment-emergent cases (2 with venlafaxine and 1 with 
milnacipran) all occurred in males and were severe. They all 
occurred either during or at the end of the uptitration period 
and they were the main reason for premature withdrawal from 
the study in 2 of the cases (1 from each treatment group).
AEs which were potentially related to the study treat-
ment and which led to definitive treatment withdrawal were 
reported in 17 patients (19%) in the milnacipran group 
(8 during uptitration, 1 at 100 mg, 4 at 150 mg and 4 at 
200 mg) and 12 patients (13%) in the venlafaxine group 
(6 during uptitration, 3 at 150 mg, and 3 at 200 mg). They 
were as follows: i) divided equally between the two groups, 
10 gastrointestinal events, 7 psychiatric events, 6 neurological 
events and 2 events of hyperhidrosis); ii) more frequent in the 
venlafaxine group: 5 psychiatric events (versus 2), iii) only 
observed in the milnacipran group: 6 events of genito-urinary 
problems in males (notably dysuria or testicular pain) and 
4 events of increase in blood pressure or heart rate.
No clinically relevant biological abnormalities were 
observed, except for increased transaminases at week 8 in 1 
patient in each group (ASAT 10 times the upper limit of 
normality [ULN] in 1 patient in the milnacipran group and 
ALAT and ASAT at 8.5 and 21 times the ULN respectively 
in 1 patient in the venlafaxine group). In both cases the values 
had returned to normal at week 24.
The two products showed a tendency to increase heart 
rate (mean increase of +4 bpm and +6 bpm at week 24 
with venlafaxine and milnacipran respectively). There 
was also a tendency for increased systolic and diastolic 
blood pressure (SBP and DBP), which was more marked 
with milnacipran (on average at week 24, for both SBP 
Figure 4 Rate of MADRs remission at weeks 8 and 24 in patients presenting at inclusion with i) a severe episode or ii) a suicide risk.
Notes: Patients with a severe episode (LOcF, n = 104). suicide risk was based on the MiNi evaluation (“Low” or “Moderate”, LOcF, n = 75).
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and DBP: +1 mmHg with venlafaxine and +4 mmHg with 
milnacipran).
There was no clinically significant lengthening of cor-
rected QT ECG interval in either group.
Discussion
The objective of this multicenter, controlled, randomized, 
double-blind study was to evaluate the efficacy and safety/
tolerability of long term administration of milnacipran at 
flexible doses of up to 200 mg/day in adults presenting with 
a moderate or severe episode of MDD. Venlafaxine was cho-
sen as the active control in this study and has recently been 
described as the treatment of reference for MDD.16,17
In the present study, which was carried out in 195 adults 
suffering from MDD, the efficacy profile of the two SNRIs 
at identical doses was found to be similar. The rates of 
responders and remissions showed no relevant differences 
between groups at all evaluation time-points, from 8 weeks to 
6 months. In clinical practice, achieving a long-lasting remis-
sion remains the major objective; after 6 months of treatment, 
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the rate of remission in the two treatments groups (50%) 
was greater than that normally reported in the literature.18 The 
similarity of the efficacy profiles of these two dual-aminergic 
antidepressants in this long term study indicates the strength 
of action of milnacipran in MDD. In addition, milnacipran 
has been shown to have comparable efficacy to clomipramine, 
another reference treatment for major depression, when given 
at equivalent doses during a period of 6 months.19
Regarding safety/tolerability, the similar incidence in 
both groups of symptoms related to the serotonergic and 
noradrenergic modes of action of the two molecules suggests 
that milnacipran and venlafaxine, at the doses administered 
(mainly 150 or 200 mg/day) have similar selectivity at NA 
and 5-HT receptors. It was noted that in men, orgasmic 
disorders were more frequent with venlafaxine, while urinary 
symptoms were more frequent with milnacipran.
The statistical power required to carry out a non-inferiority 
analysis was not achieved. However, when considering this 
limitation, it should be noted that the level of recruitment 
required to reach this statistical power proved to be unfeasible 
for a double-blind trial over this study duration (6 months). 
The statistical comparisons of efficacy presented here must 
therefore be considered to be exploratory. This does not affect 
the interest and the originality of this study, the sample size 
of which is still considerable clinically.
One of the strengths of this study was the total length 
of the protocol, which had the objective to evaluate the two 
treatments over a long period whilst maintaining the double-
blind control for 6 months of follow-up. For the outpatient 
follow-up period, the rate of study withdrawal was reasonable 
(more than two-thirds of patients finished the study), taking 
into account the fact that similar withdrawal rates have been 
reported in the literature for follow-up periods which were 
often considerably shorter.20,21 In addition, the conditions in 
which this study was carried out are similar to real-life prac-
tice; outpatient follow-up of patients, use of flexible doses 
and moderate and severe forms of the disorder.
Overall, the results of this study show that milnacipran 
and venlafaxine have similar efficacy and safety profiles 
when administered at flexible doses of up to 200 mg/day. As 
suggested by a recent meta-analysis,16 this study confirms 
milnacipran’s place among the most effective antidepressant 
molecules.
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